KRX Bio Technology Transfer Index

Oscotec is scheduled to release its Q2 2026 earnings on August 19, 2026. Analysts estimate this release will have a medium market impact (≥5%), expected.

Q2 2026 earnings release scheduled.

Alteogen's Q2 2026 earnings release on 2026-08-18 is estimated to have a medium impact (~5-10%) based on historical volatility during earnings periods scheduled.

Q2 2026 earnings release scheduled; high importance reflects anticipated market impact.

Q2 2026 earnings release scheduled. A medium impact is estimated as investors look for continued growth momentum following the strong Q1 performance.

The company is scheduled to participate in BIO Asia-Taiwan (July 15-19, 2026) to seek partners for the development and commercialization of its osteoarthritis gene therapy TG-C (formerly Invossa) in the Greater China region scheduled.

A civil court ruled against the company in a damages lawsuit on 2026-07-12, ordering compensation for 139 patients who received the gene therapy Invossa.

The company's stock price plummeted by the daily limit (~30%) on July 10, 2026, following a report that CEO Choi Ho-il stated on July 9 that the joint research with Eli Lilly does not include Tirzepatide, contrary to market expectations; the company later issued a clarification.

Received approval from the Ministry of Food and Drug Safety on 2026-07-10 for a Phase 3 clinical trial plan (IND) for 'Fexuclue' maintenance therapy, which is estimated to have a minor positive impact as a standard regulatory milestone.

On July 10, 2026, the company announced that the Phase 2 clinical trial of 'Belvarafenib' is progressing smoothly. This is estimated to have a low impact as it is a routine progress update rather than a final result, scheduled.

Received a milestone payment from Ono Pharmaceutical for the first patient dosing in a Phase 1 trial of LCB97 (ONO-7429) on 2026-07-09 expected. High impact expected as the payment exceeds 10% of annual revenue.

Announcement on July 9, 2026, that the company will proceed with the Phase 1 trial for immuno-oncology therapy ABL503 under an amended IND, adding a monotherapy cohort for new cancer types and a combination therapy arm. Clinical expansion is estimated to have a >5% price impact, scheduled.

Addition of Hong Kong's Department of Health to the list of regulatory bodies for an ongoing global clinical trial, expanding the trial's geographical scope expected. Incremental expansion of clinical trial sites generally has a minor impact on valuation.

Held 'Global R&D Day 2026' on 2026-07-08 and announced the 'LCB 2.0' strategy scheduled. Medium impact expected from the strategic shift to late-stage clinical development.

South Korea's Health Insurance Review & Assessment Service (HIRA) committee acknowledged the appropriateness of providing insurance benefits for 'Xcopri' (Cenobamate), a treatment for partial-onset seizures in adults. This is a key step towards its official launch and reimbursement in the domestic market, expected in October 2026.

Oscotec is scheduled to hold its annual 'R&D Day' on July 8, 2026, to share research progress on its ACART platform and pipeline candidates. Analysts estimate this will have a low market impact (≥1%), scheduled.

Establishment of a new R&D-specialized subsidiary, 'Neuradeon', on July 8, 2026, to focus on generics, improved drugs, and drug delivery system (DDS) research. Impact estimated at ≥1% as subsidiary formation is a long-term strategic move; scheduled

The largest individual shareholder, Shin Dong-guk, announced a plan to purchase a large block of shares (approx. 172.7 billion KRW) from the family of the eldest son, Lim Jong-yoon, on July 7, 2026. This move is estimated to have a high impact due to increased governance uncertainty in an ongoing management dispute, scheduled.

Announcement of 'ABL 2.0' strategy, including plans to advance gastric cancer treatment ABL111 directly to a global Phase 3 trial in December 2026, bypassing a full Phase 2 study, following discussions with the FDA. Bypassing Phase 2 is a major regulatory milestone with an estimated >10% price impact, scheduled.